Hepatite C Crônica/tratamento farmacológico; Transplante de Fígado; Inibidores de Proteases/uso terapêutico; Adulto; Idoso; Estudos de Coortes; Quimioterapia Combinada; Feminino; Hepatite C Crônica/virologia; Humanos; Masculino; Pessoa de Meia-Idade; Inibidores de Proteases/efeitos adversos

AFEF; ALT; AUC; BID; BOC; Boceprevir; CNI; CYP; Drug-drug interaction; EOT; EPO; EVR; Early virological response; F; FCH; French Association for the Study of the Liver; G-CSF; G1; GGT; HBV; HCC; HCV; HCV recurrence; HIV; IL; INR; IS; International Normalized Ratio; LT; Liver transplantation; M; MELD; MMF; Model for End-stage Liver Disease; NR; PCR; PI; PegIFN; Protease inhibitors; QD; RBV; RVR; SVR12; Sustained virological response; TBC; TID; TVR; Telaprevir; VB; VL; VR; alanine aminotransferase; area under the curve; boceprevir; cEVR; calcineurin inhibitors; complete early virological response; cytochrome P450; early virological response; end of treatment response rate; erythropoietin; female; fibrosing cholestatic hepatitis; gamma-glutamyl transferase; genotype 1; granulocyte colony stimulating factor; hepatitis B virus; hepatitis C virus; hepatocellular carcinoma; human immunodeficiency virus; immunosuppressive drugs; interleukin; kg; kilogram; liver transplantation; male; mycophenolate mofetil; n.a.; non-response; not available; once a day (quaque die); pegylated interferon; polymerase chain reaction; protease inhibitors; rapid virological response; ribavirin; sustained virological response 12weeks after the end of therapy; telaprevir; three times a day (ter in die); trough blood concentration; twice daily (bis in die); viral load; virological breakthrough; virological response